A phase I trial to assess the safety of 4 ml DNA C (intramuscular [IM]) [HIV DNA vaccine], and the safety and immunogenicity of DNA C followed by NYVAC C (IM) [HIV vaccine] in an open, randomised comparison to NYVAC C alone in healthy volunteers at low risk of human immunodeficiency virus infection.

Trial Profile

A phase I trial to assess the safety of 4 ml DNA C (intramuscular [IM]) [HIV DNA vaccine], and the safety and immunogenicity of DNA C followed by NYVAC C (IM) [HIV vaccine] in an open, randomised comparison to NYVAC C alone in healthy volunteers at low risk of human immunodeficiency virus infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs HIV DNA vaccine; HIV vaccine
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms EuroVacc-02
  • Most Recent Events

    • 20 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 12 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top